Willcocks A L, Challiss R A, Nahorski S R
Department of Pharmacology and Therapeutics, University of Leicester, U.K.
Eur J Pharmacol. 1990 Sep 18;189(2-3):185-93. doi: 10.1016/0922-4106(90)90022-p.
The equilibrium and kinetic binding characteristics of D-inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) have been studied in membrane preparations of rat cerebellum and bovine adrenal cortex. Saturation analysis of isotopic dilution binding data demonstrated apparent KD values for Ins(1,4,5)P3 binding of 23 +/- 5 nM and 3.0 +/- 1.3 nM for cerebellar and adrenal cortical preparations, respectively, with approximately 20-fold greater receptor density present in the cerebellar preparation (Bmax: 10.2 +/- 2.5 pmol/mg protein). Kinetic analysis confirmed the equilibrium binding-derived KD value for cerebellum (KD: 39.9 nM), but revealed a second, very high affinity site (KD: 0.06 nM) to be present in adrenal cortex. The affinity differences between the investigated preparations was also observed with respect to the IC50 values obtained for inhibition of specific [3H]Ins(1,4,5)P3 binding by a number of inositol polyphosphate analogues including D-inositol 2,4,5-trisphosphate, DL-inositol 1,4,5-trisphosphorothioate and L-Ins(1,4,5)P3. In contrast, the Ins(1,4,5)P3-receptor antagonist heparin displayed greater potency for the cerebellar (IC50: 16.5 +/- 6.2 micrograms . ml-1) compared to the adrenal cortical preparation (IC50: 51.0 +/- 6.1 micrograms . ml-1). The apparent differences between the Ins(1,4,5)P3 receptors characterized in the two tissue preparations are discussed.
已在大鼠小脑和牛肾上腺皮质的膜制剂中研究了D-肌醇1,4,5-三磷酸(Ins(1,4,5)P3)的平衡和动力学结合特性。对同位素稀释结合数据的饱和分析表明,小脑和肾上腺皮质制剂中Ins(1,4,5)P3结合的表观KD值分别为23±5 nM和3.0±1.3 nM,小体制剂中的受体密度大约高20倍(Bmax:10.2±2.5 pmol/mg蛋白质)。动力学分析证实了小脑的平衡结合衍生KD值(KD:39.9 nM),但显示肾上腺皮质中存在第二个非常高亲和力的位点(KD:0.06 nM)。在通过多种肌醇多磷酸类似物(包括D-肌醇2,4,5-三磷酸、DL-肌醇1,4,5-三硫代磷酸酯和L-Ins(1,4,5)P3)抑制特异性[3H]Ins(1,4,5)P3结合所获得的IC50值方面,也观察到了所研究制剂之间的亲和力差异。相比之下,Ins(1,4,5)P3受体拮抗剂肝素对小脑的效力(IC50:16.5±6.2微克·ml-1)高于肾上腺皮质制剂(IC50:51.0±6.1微克·ml-1)。讨论了两种组织制剂中所表征的Ins(1,4,5)P3受体之间的明显差异。